Related Experiment Video

Updated: Aug 9, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

[Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney]

Wei Wang1, Xiao-hui Guo, Hong-hua Wu

  • 1Department of Endocrinology, Peaking University First Hospital, Beijing 100034, China.

Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences
|April 18, 2006
PubMed
Abstract

Insights

Obesity-induced kidney damage in OLETF rats is linked to abnormal renal lipid metabolism, specifically increased triglyceride (TG) content. Fenofibrate and metformin treatments reduced kidney damage by lowering SREBP-1, a key protein in fat synthesis.

Area of Science:

  • Biochemistry
  • Nephrology
  • Metabolic Syndrome

Context:

  • Obesity and hyperglycemia in Otsuka Long-Evans Tokushima Fatty (OLETF) rats lead to renal damage.
  • Renal lipid metabolism plays a crucial role in the pathogenesis of diabetic nephropathy.
  • Understanding the molecular mechanisms of renal lipid accumulation is vital for developing effective treatments.

Purpose:

  • To investigate the molecular mechanisms underlying abnormal renal lipid metabolism in OLETF rats.
  • To evaluate the therapeutic effects of fenofibrate and metformin on renal lipid metabolism and damage in OLETF rats.

Summary:

  • OLETF rats exhibited obesity, hyperglycemia, and hyperlipidemia, progressing to renal damage characterized by increased 24-hour urine albumin and kidney triglyceride (TG) content.
  • Elevated levels of Sterol Regulatory Element-Binding Protein-1 (SREBP-1) protein, Fatty Acid Synthase (FAS) mRNA, and Acetyl-CoA Carboxylase (ACC) mRNA were observed in OLETF rat kidneys.
  • Fenofibrate and metformin treatments significantly reduced SREBP-1 protein and FAS/ACC mRNA expression, ameliorating renal damage and TG deposition.

Impact:

  • This study elucidates the role of SREBP-1 in renal lipid accumulation and diabetic nephropathy.
  • Fenofibrate and metformin demonstrate potential therapeutic benefits in managing kidney complications associated with metabolic disorders.
  • The findings provide a molecular basis for targeting lipid metabolism pathways to prevent or treat kidney disease in obese and diabetic individuals.

More Related Videos

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes11:03

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Published on: September 9, 2021

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...